8-K: Foghorn Therapeutics Announces First Quarter 2025 Financial Results and Corporate Update

Foghorn Therapeutics reported its Q1 2025 financial results, highlighting progress in its clinical and preclinical programs and a cash runway into 2027.

Summary

• Foghorn Therapeutics announced its first quarter 2025 financial results.
• The company's FHD-909 Phase 1 dose escalation trial is progressing in SMARCA4 mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target.
• Data presented at AACR showed synergistic activity of FHD-909 in combination with pembrolizumab and KRAS inhibitors.
• The selective CBP degrader is on track for IND-enabling studies, targeting an IND in 2026.
• Continued progress is being made on the Selective EP300 degrader and Selective ARID1B degrader programs, with updates expected in H2 2025.
• The company's cash, cash equivalents, and marketable securities totaled $220.6 million as of March 31, 2025, providing a cash runway into 2027.
• Collaboration revenue for the quarter was $6.0 million, compared to $5.1 million in the same period of 2024.
• Research and development expenses were $21.6 million, compared to $25.5 million in the first quarter of 2024.
• Net loss for the quarter was $18.8 million, compared to a net loss of $25.0 million for the same period in 2024.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with progress in clinical trials, strong financial position, and strategic collaborations. However, the company is still operating at a net loss, which tempers the overall sentiment.

Positives

• FHD-909 shows promise in combination with other therapies for NSCLC.
• The company has a strong cash position, providing a runway into 2027.
• The Lilly collaboration is progressing well, contributing to increased collaboration revenue.
• The company is advancing multiple programs towards IND filings.
• Preclinical data supports combination opportunities for selective CBP degraders in solid tumors beyond EP300-mutant cancers.
• Selective EP300 degradation is effective in IMiD-resistant MM cell lines.

Negatives

• The company continues to operate at a net loss, with a loss of $18.8 million for the quarter.
• Research and development expenses remain significant, although they decreased compared to the previous year.

Risks

• Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict.
• Clinical trials may not yield the expected results.
• Regulatory approvals for product candidates are not guaranteed.
• The company's business is subject to substantial risks and uncertainties as detailed in its SEC filings.

Future Outlook

Foghorn expects its current cash balance to fund operations into 2027 and anticipates advancing multiple programs towards IND filings and clinical trials.

Management Comments

• Adrian Gottschalk, President and Chief Executive Officer of Foghorn, stated that the FHD-909 combination data reinforces the expansive potential of the selective SMARCA2 inhibitor program in non-small cell lung cancer.
• Mr. Gottschalk also noted that advancements with FHD-909 and pipeline programs underscore the company's track record and leadership in engineering promising selective therapeutics.
• Mr. Gottschalk stated that with a robust balance sheet and cash runway into 2027, the company is in a strong position to deliver significant value with differentiated, high-impact therapeutics in 2025 and beyond.

Industry Context

Foghorn is focused on chromatin biology, a field implicated in up to 50% of all tumors, and is developing precision medicines targeting genetically determined dependencies within the chromatin regulatory system. The company's approach aims to unlock selectivity of previously undruggable targets and innovate selective protein degradation.

Comparison to Industry Standards

• Foghorn's approach to selectively inhibit SMARCA2 is notable, as the industry has faced challenges in developing selective inhibitors for this target.
• The company's selective CBP and EP300 degraders aim to overcome toxicity issues associated with dual inhibition, a common problem in the field.
• Foghorn's collaboration with Lilly, a leading oncology company, provides validation of its technology and approach.
• The company's focus on protein degradation and induced proximity modalities aligns with current trends in drug discovery.
• The company's cash runway into 2027 provides a competitive advantage compared to other biotechnology companies.

Management Changes

Stakeholder Impact

• Shareholders: The company's progress in clinical trials and strong financial position are positive for shareholders.
• Employees: The company's growth and advancement of programs provide opportunities for employees.
• Patients: The company's development of novel therapies has the potential to improve outcomes for patients with cancer.
• Partners: The company's collaboration with Lilly is beneficial for both companies.

Next Steps

• Continue Phase 1 trial of FHD-909 in SMARCA4-mutated cancers.
• Advance Selective CBP degrader program towards IND-enabling studies.
• Provide program updates on Selective EP300 degrader and Selective ARID1B degrader programs in H2 2025.
• Target IND filing for Selective CBP degrader in 2026.
• Target IND filing for Selective EP300 degrader in 2026.

Key Dates

Keywords

Foghorn Therapeutics, FHD-909, SMARCA2, SMARCA4, CBP degrader, EP300 degrader, ARID1B degrader, Oncology, Gene Traffic Control Platform, Clinical trial, Preclinical data, Financial results, Collaboration, Lilly, NSCLC, Protein degradation, Chromatin biology